[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
[2] |
Goldhirsch A, Winer EP, Coates AS. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J]. Ann Oncol,2013, 24(9): 2206-2223.
|
[3] |
Wu SY, Tan Y, Guan YS. Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer[J]. Zhonghua Gan Zang Bing Za Zhi, 2016, 24(6): 422-428.
|
[4] |
Gong Y, Liu YR, Ji P, et al. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study [J]. Sci Rep, 2017, 7: 45 411.
|
[5] |
何永鹏,李丽仙,易琳,等. 乳腺癌患者血清HER-2胞外域水平与癌组织HER-2表达的相关性及其临床意义[J/CD]. 中华乳腺病杂志(电子版), 2016, 10(1): 14-19.
|
[6] |
Kimbung S, Kovács A, Bendahl PO, et al. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences [J]. Mol Oncol, 2014, 8(1): 119-128.
|
[7] |
Tabariès S, Dupuy F, Dong Z, et al. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes [J]. Mol Cell Biol, 2012, 32(15): 2979-2991.
|
[8] |
Tabariès S, Annis MG, Hsu BE, et al. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis [J]. Oncotarget, 2015, 6(11): 9476-9487.
|
[9] |
Daniele A, Abbate I, Oakley C, et al. Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review [J]. Int J Biochem Cell Biol, 2016, 77 (Pt A): 91-101.
|
[10] |
Mehner C, Hockla A, Miller E, et al. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer [J]. Oncotarget, 2014, 5(9): 2736-2749.
|
[11] |
Tabariès S, Ouellet V, Hsu BE,et al. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases [J]. Breast Cancer Res, 2015, 17: 45.
|
[12] |
Golubnitschaja O, Yeghiazaryan K, Stricker H, et al. Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours [J]. BMC Cancer, 2016, 16: 357
|
[13] |
Shabo I, Olsson H, Stal O, et al. Breast cancer expression of DAP12 is associated with skeletal and liver metastases and poor survival [J]. Clin Breast Cancer, 2013, 13(5): 371-377.
|
[14] |
Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells [J]. Adv Exp Med Biol, 2011, 714: 141-150.
|
[15] |
Zheng P, Liu YX, Chen L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer [J]. J Proteome Res, 2010, 9(10): 4897-4905.
|
[16] |
Hao RT, Zhang XH, Pan YF, et al. Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer [J]. J Cancer Res Clin Oncol, 2010, 136(9): 1349-1357.
|
[17] |
Wang L, Peng L, Dong B, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome [J]. Ann Oncol, 2006, 17(10): 1517-1522.
|
[18] |
Ustaalioglu BB, Bilici A, Barisik NO, et al. Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer [J]. Clin Transl Oncol, 2012, 14(12): 911-922.
|
[19] |
Zeng Q, Dong JM, Guo K, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis [J]. Cancer Res, 2003, 63(11): 2716-2722.
|
[20] |
Kato H, Semba S, Miskad UA, et al. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases [J]. Clin Cancer Res, 2004, 10(21): 7318-7328.
|
[21] |
Lv J, Liu C, Huang H, et al. Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3 [J]. Gene Ther, 2013, 20(8): 834-845.
|
[22] |
López-Knowles E, O'Toole SA, Mcneil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality [J]. Int J Cancer, 2010, 126(5): 1121-1131.
|
[23] |
Pierobon M, Ramos C, Wong S, et al. Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer [J]. Clin Cancer Res, 2017, 23(16): 4919-4928.
|
[24] |
Creighton CJ, Fu X, Hennessy BT, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer [J]. Breast Cancer Res, 2010, 12(3): R40.
|
[25] |
孙子涵,潘沁汶,苑龙,等. ERβ和PTEN在人乳腺癌组织中的表达及其临床意义[J/CD]. 中华乳腺病杂志(电子版), 2016, 10(5): 276-281.
|
[26] |
Bleckmann A, Conradi LC, Menck K, et al. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases [J]. Clin Exp Metastasis, 2016, 33(4): 309-323.
|
[27] |
Najafov A, Seker T, Even I, et al. MENA is a transcriptional target of the Wnt/beta-catenin pathway [J]. PLoS One, 2012, 7(5): e37013.
|
[28] |
Corda G, Sala G, Lattanzio R, et al. Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer [J]. J Pathol, 2017, 241(3): 350-361.
|
[29] |
Säfholm A, Tuomela J, Rosenkvist J, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility [J]. Clin Cancer Res, 2008, 14(20): 6556-6563.
|
[30] |
Vidal-Vanaclocha F. Architectural and functional aspects of the liver with implications for cancer metastasis[M]//Brodt P. Liver metastasis: biology and clinical management. Dordrecht: Springer, 2011: 9-42.
|
[31] |
Elvevold K, Smedsrød B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity [J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294(2): G391-400.
|
[32] |
Porquet N, Huot J. Signal transduction in tumor-endothelial cell communication[M]// Brodt P. Liver metastasis: biology and clinical management. Dordrecht: Springer, 2011: 187-212.
|
[33] |
Kelwick R, Wagstaff L, Decock J, et al. Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15 [J]. Int J Cancer, 2015, 136(4): E14-26.
|
[34] |
Wu W, Chen J, Ye W, et al. Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study [J]. Breast Cancer Res Treat, 2017,166(1): 289-297.
|